tradingkey.logo

Regulus Therapeutics Inc <RGLS.OQ> expected to post a loss of 24 cents a share - Earnings Preview

ReutersMay 5, 2025 8:04 PM
  • Regulus Therapeutics Inc RGLS.OQ RGLS.O is expected to show no change in quarterly revenue when it reports results on May 7 (estimated) for the period ending March 31 2025

  • ​LSEG's mean analyst estimate for Regulus Therapeutics Inc is for a loss of 24 cents per share.

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," 4 "hold" and no "sell" or "strong sell."

  • The mean earnings estimate of analysts was unchanged in the last three months. ​

  • Wall Street's median 12-month price target for Regulus Therapeutics Inc is $9.00​, above​ its last closing price of $7.85. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING

STARMINESMARTESTIMATE®

LSEG IBES ESTIMATE

ACTUAL

BEAT, MET, MISSED

SURPRISE %

Dec. 31 2024

-0.21

-0.20

Beat

4.8

Sep. 30 2024

-0.18

-0.17

-0.21

Missed

-23.5

Jun. 30 2024

-0.16

-0.15

-0.17

Missed

-15.9​

Mar. 31 2024

-0.26

-0.22

-0.29

Missed

-30.3

​​Dec. 31 2023

-0.40

-0.39

-0.40

Missed

-1.3

Sep. 30 2023

-0.41

-0.40

-0.40

Met

-0.8​

Jun. 30 2023

-0.41

-0.41

-0.37

Beat

9.8

Mar. 31 2023

-0.44

-0.44

-0.42

Beat

3.8

This summary was machine generated May 5 at 20:04 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI